IL3RA and acute myeloid leukemia: The non-Fc-engineered CD123 monoclonal antibody did not induce anti-leukemic activity in AML patients; therefore, monoclonal antibody blockade of CD123 function solely seemed insufficient as a therapeutic strategy [63].